Icon Group

Icon Group is a renowned healthcare enterprise dedicated to providing integrated healthcare services across multiple countries including Australia, New Zealand, Singapore, Hong Kong, Mainland China, Malaysia, and the United Kingdom. The group's scope of services encompasses day oncology, radiation oncology, chemotherapy compounding, pharmacy management, research, and clinical trials, solidifying its position as a leading player in the Health Care industry. Established in 1988, the organization's ethos centers around delivering the optimal care to a broader demographic, closer to their residences, encapsulated in their slogan "Dedicated to delivering the best care possible, to as many people as possible, as close to home as possible." Icon holds a dominant presence in the oncology domain, with its day oncology division being the largest private provider of day oncology and haematology in Australia and across international centers in Singapore, Hong Kong, and New Zealand. The acquisition of four key radiation oncology businesses has further fortified its position, boasting world-class services equipped with cutting-edge technology and treatment methodologies. Additionally, its subsidiary, Slade Health, stands out as one of Australia’s largest chemotherapy compounders, administering over 1,000,000 infusions annually and expanding its reach globally. The company's pharmacy management arms, Epic Pharmacy and Slade Pharmacy, are at the forefront of pharmaceutical supply for the hospital and oncology sectors in Australia. Moreover, Icon Group's commitment to research and clinical trials is evident through Australia's largest private cancer clinical trials program and a burgeoning global footprint. With a comprehensive end-to-end service model, the company functions as a cohesive multidisciplinary team to deliver exceptional care. Emphasizing innovation and technology, it has forged global partnerships with industry leaders such as Varian and the Union for International Cancer Control (UICC), positioning itself at the vanguard of cancer treatment. Although details regarding the last investment and associated investors are currently undisclosed, Icon's expansive reach, coupled with its focus on innovation and collaboration, renders it a compelling entity in the healthcare ecosystem.